Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B

Open access
Chowdary, Pratima, Shapiro, Susan, Makris, Mike, Evans, Gillian, Boyce, Sara, Talks, Kate, Dolan, Gerard, Reiss, Ulrike, Phillips, Mark, Riddell, Anne, Peralta, Maria R., Quaye, Michelle, Patch, David W., Tuddenham, Edward, Dane, Allison, Watissée, Marie, Long, Alison, Nathwani, Amit · 2022 · New England Journal of Medicine

Abstract

BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B. METHODS: In this multicenter, open-label, phase 1-2 trial, we assessed the safety and efficacy of varying doses of FLT180a in patients with severe or moderately severe hemophilia B (factor IX level, ≤2% of normal value). All the patients received glucocorticoids with or without tacrolimus for immunosuppression to decrease the risk of vector-related immune responses. After 26 weeks, patients were enrolled in a long-term follow-up study. The primary end points were safety and efficacy, as assessed by factor IX levels at week 26. RESULTS: vg. After receiving the infusion, all the patients had dose-dependent increases in factor IX levels. At a median follow-up of 27.2 months (range, 19.1 to 42.4), sustained factor IX activity was observed in all the patients except one, who resumed factor IX prophylaxis. As of the data-cutoff date (September 20, 2021), five patients had normal factor IX levels (range, 51 to 78%), three patients had levels from 23 to 43%, and one had a level of 260%. Of the reported adverse events, approximately 10% were related to FLT180a and 24% to immunosuppression. Increases in liver aminotransferase levels were the most common FLT180a-related adverse events. Late increases in aminotransferase levels occurred in patients who had received prolonged tacrolimus beyond the glucocorticoid taper. A serious adverse event of arteriovenous fistula thrombosis occurred in the patient with high factor IX levels. CONCLUSIONS: Sustained factor IX levels in the normal range were observed with low doses of FLT180a but necessitated immunosuppression with glucocorticoids with or without tacrolimus. (Funded by Freeline Therapeutics; ClinicalTrials.gov numbers, NCT03369444 and NCT03641703; EudraCT numbers, 2017-000852-24 and 2017-005080-40.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2119913

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 159

Metadata

Authors
Chowdary, P., Shapiro, S., Makris, M., Evans, G., Boyce, S., Talks, K., Dolan, G., Reiss, U., Phillips, M., Riddell, A., Peralta, M. R., Quaye, M., Patch, D. W., Tuddenham, E., Dane, A., Watissée, M., Long, A., & Nathwani, A.
Venue
New England Journal of Medicine
Published
2022-07-21
Volume
387
Issue
3
Pages
237-247
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4285992907
Cited by
159
References
11
FWCI
22.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. https://app.cochat.ai/papers/10.1056/nejmoa2119913
The paper
Chowdary, P., Shapiro, S., Makris, M., Evans, G., Boyce, S., Talks, K., Dolan, G., Reiss, U., Phillips, M., Riddell, A., Peralta, M. R., Quaye, M., Patch, D. W., Tuddenham, E., Dane, A., Watissée, M., Long, A., & Nathwani, A. (2022). Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2119913

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.